Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald Sells 1,440 Shares of Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the sale, the executive vice president now owns 12,881 shares in the company, valued at approximately $3,240,344.36. The trade was a 10.06 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Friday, February 14th, Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $255.21, for a total value of $169,204.23.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $250.00 on Wednesday. The business has a 50 day simple moving average of $253.96 and a two-hundred day simple moving average of $263.29. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The stock has a market capitalization of $32.25 billion, a P/E ratio of -95.42 and a beta of 0.35. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.24 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Morgan Stanley boosted their price objective on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Chardan Capital reissued a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. Raymond James boosted their price objective on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Finally, Scotiabank decreased their price objective on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $299.48.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Focus Partners Advisor Solutions LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $203,000. Worldquant Millennium Advisors LLC grew its position in shares of Alnylam Pharmaceuticals by 156.6% in the fourth quarter. Worldquant Millennium Advisors LLC now owns 150,191 shares of the biopharmaceutical company’s stock valued at $35,341,000 after purchasing an additional 91,671 shares in the last quarter. Zurich Insurance Group Ltd FI purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $6,583,000. Vident Advisory LLC grew its position in Alnylam Pharmaceuticals by 21.2% in the fourth quarter. Vident Advisory LLC now owns 1,327 shares of the biopharmaceutical company’s stock worth $312,000 after acquiring an additional 232 shares during the period. Finally, Soleus Capital Management L.P. grew its position in Alnylam Pharmaceuticals by 29.3% in the fourth quarter. Soleus Capital Management L.P. now owns 76,800 shares of the biopharmaceutical company’s stock worth $18,072,000 after acquiring an additional 17,400 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.